Thursday, October 1
17:30-18:00 Meet the Expert (MTE) Session
Friday, October 2
08:00-08:15 “Good morning” Coffee
08:15-08:30 Welcome Note by Congress Co-Chairs
08:30-10:00 Session 1: AML and graft manipulation 
Controversy: Will graft manipulation replace PTCy?
Moderator: Nicolaus Kröger, Germany
08:30-08:45 Yes: Lori Muffly, USA
08:45-09:00 No: Rainer Storb, USA
Controversy: Is 3+7 induction in AML prior to alloHSCT still the standard in 2026?
Moderator: Arnon Nagler, Israel
09:00-09:15 Yes: Charles Craddock, UK
09:15-09:30 No: Alexander Perl, USA
09:30-10:00 Panel discussion: All session faculty
10:00-10:30 Coffee Break, Poster Viewing and Visit Exhibition
10:30-11:30 Industry-supported Symposium
11:30-11:40 Technical Break
11:40-13:10 Session 2: CAR T in NHL
Controversy: Is in-vivo CAR T the future of CAR T cell therapy in NHL?
Moderator: Michael Bishop, USA
11:40-11:55 Yes: TBA
11:55-12:10 No: Marion Subklewe, Germany
Controversy: Should CAR T be preferred as first choice instead of bispecific antibodies for RR NHL (FL, CLL)?
Moderator: Marion Subklewe, Germany
12:10-12:25 Yes: Michael Bishop, USA
12:25-12:40 No: Gloria Iacoboni, Spain
12:40-13:10 Panel discussion: All session faculty
13:10-13:45 Lunch Break, Poster Viewing and Visit Exhibition
13:45-14:45 Industry-supported Lunch Symposium
14:45-15:00 Short Break
15:00-16:30 Session 3: PTCy and clinical endpoints
Controversy: Does PTCy as GVHD prophylaxis increase the risk of relapse?
Moderator: Hildegard Greinix, Austria
15:00-15:15 Yes: Avichai Shimoni, Israel
15:15-15:45 No: Arnon Nagler, Israel
Controversy: Is GRFS the best endpoint for transplant trials? 
Moderator: Charles Craddock, UK
15:45-16:00 Yes: Shernan Holtan, USA
16:00-16:15 No: Robert Soiffer, USA
16:15-16:30 Panel discussion: All session faculty
16:30-17:00 Coffee Break, Poster Viewing and Visit Exhibition
17:00-18:30 Session 4: Multiple myeloma
Controversy: Can we omit autologous HSCT in MRD negative patients?
Moderator: Maximillian Merz, Germany
17:00-17:15 Yes: TBA
17:15-17:30 No: Pieter Sonneveld, Netherlands
Controversy: Should bispecific combination be preferred to CAR T in myeloma?
Moderator: Pieter Sonneveld, Netherlands
17:30-17:45 Yes: Yael Cohen, Israel
17:45-18:00 No: Maximillian Merz, Germany
18:00-18:30 Panel discussion: All session faculty
Saturday, October 3
08:30-10:00 Session 5: ALL
Controversy: Is there still a role for chemotherapy and transplantation in adult PH+ ALL?
Moderator: Mutlu Arat, Turkey
08:30-08:45 Yes: Jaime Sanz Caballer, Spain
08:45-09:00 No: Robin Foà, Italy
Controversy: Is there still a role for allo in ALL in the era of CAR T cell?
Moderator: Robert Soiffer, USA
09:00-09:15 Yes: Peggy Lu, China
09:15-09:30 No: TBA
09:30-10:00 Panel discussion: All session faculty
10:00-10:20 Coffee Break, Poster Viewing and Visit Exhibition
10:20-11:30 Session 6: PTLD
Controversy: Is PTLD still the problem in the era of modern GVHD prevention?
Moderator: Jan Styczynski, Poland
10:20-10:30 Yes: Andrea Bacigalupo, Italy
10:30-10:40 No: Zinaida Perić, Croatia
Controversy: Should cell therapy be the first-line treatment in PTLD? 
Moderator: Olaf Penack, Germany
10:40-10:50 Yes: TBA
10:50-11:00 No: Marcos de Lima, USA
11:00-11:30 Panel discussion: All session faculty
11:30-13:30 Session 7: Donor selection and GVHD prophylaxis
Controversy: Should all donors be screened for germline mutations?
Moderator: Nico Gagelmann, Germany
11:30-11:45 Yes: Carmelo Gurnari, Italy
11:45-12:00 No: Bronwen Shaw, USA
Controversy: Should PTCy be added to ATLG/ATG to prevent GVHD? 
Moderator: Francesca Bonifazi, Italy
12:00-12:15 Yes: Nihar Desai, Canada
12:15-12:30 No: Marie Thérèse Rubio, France
12:30-13:00 Panel discussion: All session faculty
13:00-13:30 Lunch Break, Poster Viewing and Visit Exhibition
13:30-15:00 Industry-supported Lunch Symposium
15:00-15:10 Short Break
15:10-16:40 Session 8: MRD
Controversy: Are we ready for personalized pre-allo conditioning regimens for AML based on MRD status?
Moderator: Thomas Schroeder, Germany
15:10-15:25 Yes: Christopher Hourigan, USA
15:25-15:40 No: Felicitas Thol, Germany
Controversy: Is MRD prior to allograft relevant for MDS?
Moderator: Fernando Barroso Duarte, Brazil
15:40-15:55 Yes: TBA
15:55-16:10 No: Magnus Tobiasson, Sweden
16:10-16:40 Panel discussion: All session faculty
16:40-17:00 Coffee Break, Poster Viewing and Visit Exhibition
17:00-18:30 Session 9: Hemoglobinopathy and aplastic anemia
Controversy: Should we do for gene therapy instead of SCT?
Moderator: Carlo Dufour, Italy
17:00-17:15 Yes: Franco Locatelli, Italy
17:15-17:30 No: Emmanuele Angelucci, Italy
17:30-17:45 Discussion
Controversy: Can haplo-identical HSCT be offered as first line treatment for severe aplastic anemia?
Moderator: Carlo Dufour, Italy
17:45-18:00 Yes: Xiaojun Huang, China
18:00-18:15 No: Antonio Risitano, Italy
18:15-18:30 Discussion
18:30 Poster Walk and Awards Session (Poster Area)
Sunday, October 4
09:00-10:30 Session 10: Complications I
Controversy: Can peritransplant JAK inhibitor reduce GvHD and cytopenia in patients with myelofibrosis post allograft? 
Moderator: Alessandro Rambaldi, Italy
09:00-09:15 Yes: Yi-Bin Chen, USA
09:15-09:30 No: Bart Lee Scott, USA
Controversy: Is transplant associated TMA an underestimated complication?
Moderator: Alessandro Rambaldi, Italy
09:30-09:45 Yes: Sumithira Vasu, USA
09:45-10:00 No: Eleni Gavriilaki, Greece
10:00-10:30 Panel discussion: All session faculty
10:30-11:00 Coffee Break
11:00-12:30 Session 11: Complications II
Controversy: Is combination therapy the future of chronic GVHD?
Moderator: Yi-Ben Chen, USA
11:00-11:15 Yes: Daniele Avenoso, Italy
11:15-11:30 No: Hildegard Greinix, Austria
Controversy: Does early use of MSC prevent graft failure and GVHD?
Moderator: Ivan Moiseev, Russia
11:30-11:45 Yes: Zhang Xi, China
11:45-12:00 No: Francesca Bonifazi, Italy
12:00-12:30 Panel discussion: All session faculty
12:30 Closing Remarks